10x Genomics Partners with Brigham & Women's Hospital to Transform Blood-Based Diagnostics for Autoimmune Diseases 10x Genomics initiates a research collaboration with Brigham & Women's Hospital to enhance blood diagnostics for autoimmune diseases, improving patient care through advanced genomic techniques.

10x Genomics Partners with Brigham & Women's Hospital to Transform Blood-Based Diagnostics for Autoimmune Diseases #United_States #Pleasanton #Autoimmune_Disease #10x_Genomics #Brigham_Women's_Hospital

EVOQ Therapeutics Secures $2 Million NIH Grant for Celiac Disease Treatments EVOQ Therapeutics has received a $2 million grant from the NIH to enhance therapies for celiac disease, an autoimmune condition affecting millions. This funding accelerates their innovative research.

EVOQ Therapeutics Secures $2 Million NIH Grant for Celiac Disease Treatments #USA #Ann_Arbor #Autoimmune_Disease #Celiac_Disease #EVOQ_Therapeutics

[Audio] Original post on wnyc.org

The Nobel Prize for Understanding Autoimmune Disease The Nobel Prize in physiology or medicine was awarded to three scientists for their work in immunology. Daniel Griffin , MD, PhD, Chief of In...

#immunology #infectious_disease #autoimmune_disease #local_wnyc #covid_vaccine #medicine […]

Leads Biolabs Announces FDA Approval for LBL-047, a Novel Autoimmune Therapy Leads Biolabs has received FDA approval for LBL-047, an innovative bispecific fusion protein targeting autoimmune diseases, marking a significant milestone in treatment development.

Leads Biolabs Announces FDA Approval for LBL-047, a Novel Autoimmune Therapy #China #Leads_Biolabs #Nanjing #Autoimmune_Disease #LBL-047

The Rapid Growth of Autoimmune Disease Diagnostics Market Expected to Hit $11.45 Billion by 2032 The autoimmune disease diagnostics market is projected to achieve a significant valuation of $11.45 billion by 2032, driven by innovative technologies and rising disease awareness.

The Rapid Growth of Autoimmune Disease Diagnostics Market Expected to Hit $11.45 Billion by 2032 #United_States #Market_Growth #Redding #diagnostics #Autoimmune_Disease

Keymed Biosciences' CM336 Shows Promising Results in Latest Clinical Trials for Autoimmune Diseases Keymed Biosciences has released groundbreaking findings on CM336, a bispecific antibody treatment for autoimmune hemolytic anemia, demonstrating rapid efficacy and sustained remission.

Keymed Biosciences' CM336 Shows Promising Results in Latest Clinical Trials for Autoimmune Diseases #China #Chengdu #Autoimmune_Disease #Keymed_Biosciences #CM336

Lupus Research Alliance Brings Focus to Lupus Awareness Month with Community Initiatives The Lupus Research Alliance is leading efforts this May to raise awareness for lupus, a misunderstood autoimmune disease affecting millions globally.

Lupus Research Alliance Brings Focus to Lupus Awareness Month with Community Initiatives #USA #New_York #Lupus_Research_Alliance #Autoimmune_Disease #Lupus_Awareness_Month

AbolerIS Pharma Establishes Scientific Advisory Board for Advancing Treatment of Autoimmune Diseases AbolerIS Pharma has announced the formation of its Scientific Advisory Board to push forward its lead program ABO21009 for rheumatoid arthritis and beyond.

AbolerIS Pharma Establishes Scientific Advisory Board for Advancing Treatment of Autoimmune Diseases #Belgium #Autoimmune_Disease #AbolerIS_Pharma #ABO21009 #Gosselies

Mozart Therapeutics Achieves Milestone with Successful MTX-101 Phase 1a Study Results Mozart Therapeutics has successfully completed its Phase 1a study of MTX-101 in healthy adults, showcasing promising safety and pharmacokinetics, paving the way for advancing treatments for autoimmune diseases.

Mozart Therapeutics Achieves Milestone with Successful MTX-101 Phase 1a Study Results #USA #Seattle #Autoimmune_Disease #Mozart_Therapeutics #MTX-101

Celebrating A Decade of Changing Lives: The World Lupus Federation's Impact The World Lupus Federation marks its 10th anniversary, highlighting vital strides made in lupus awareness, education, and patient advocacy worldwide.

Celebrating A Decade of Changing Lives: The World Lupus Federation's Impact #United_States #Washington #Autoimmune_Disease #World_Lupus_Federation #Lupus_Foundation

RheumaGen, Inc. Secures $15 Million Series A to Transform Autoimmune Treatment with Gene Editing RheumaGen, Inc. has launched with $15 million in Series A financing, aiming to develop innovative HLA gene-editing therapies targeting major autoimmune diseases, specifically rheumatoid arthritis.

RheumaGen, Inc. Secures $15 Million Series A to Transform Autoimmune Treatment with Gene Editing #United_States #Aurora #Autoimmune_Disease #Gene_Editing #RheumaGen

Hansa Biopharma Completes Patient Enrollment in Pivotal Trial for Imlifidase in Treating Rare Autoimmune Disease Hansa Biopharma has successfully completed patient enrollment in the pivotal GOOD-IDES-02 trial for imlifidase, targeting anti-glomerular basement membrane disease, a rare autoimmune condition.

Hansa Biopharma Completes Patient Enrollment in Pivotal Trial for Imlifidase in Treating Rare Autoimmune Disease #Sweden #Lund #Hansa_Biopharma #imlifidase #Autoimmune_Disease

#invisibleillness, #Myathenia_Gravis
#autoimmune_disease